EA202092554A1 - COMPOSITIONS FOR TREATMENT OF SKIN DISEASES - Google Patents

COMPOSITIONS FOR TREATMENT OF SKIN DISEASES

Info

Publication number
EA202092554A1
EA202092554A1 EA202092554A EA202092554A EA202092554A1 EA 202092554 A1 EA202092554 A1 EA 202092554A1 EA 202092554 A EA202092554 A EA 202092554A EA 202092554 A EA202092554 A EA 202092554A EA 202092554 A1 EA202092554 A1 EA 202092554A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
treatment
skin
metabolites
skin diseases
Prior art date
Application number
EA202092554A
Other languages
Russian (ru)
Inventor
Пол Вагнер
Original Assignee
Форте Сабсидиари, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Форте Сабсидиари, Инк. filed Critical Форте Сабсидиари, Инк.
Priority claimed from PCT/US2019/030444 external-priority patent/WO2019217203A1/en
Publication of EA202092554A1 publication Critical patent/EA202092554A1/en

Links

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

В настоящем документе описаны способы и композиции для лечения связанных с дисбиозом кожных заболеваний. Дополнительно в настоящем документе описано применение метаболитов для лечения нарушения регуляции микробиоты у субъекта. Такие метаболиты могут быть произведены микроорганизмами, присутствующими в большем количестве в коже здоровых субъектов по сравнению с кожей субъекта, у которого имеется дисбиоз кожи. Кроме того, представленные в настоящем документе композиции и способы описывают применение метаболитов как часть комбинированного способа лечения.Methods and compositions for the treatment of dysbiosis-related skin diseases are described herein. Additionally, this document describes the use of metabolites to treat a dysregulated microbiota in a subject. Such metabolites can be produced by microorganisms present in greater amounts in the skin of healthy subjects as compared to the skin of a subject who has skin dysbiosis. In addition, the compositions and methods provided herein describe the use of metabolites as part of a combination treatment.

EA202092554A 2018-07-26 2019-05-02 COMPOSITIONS FOR TREATMENT OF SKIN DISEASES EA202092554A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862703737P 2018-07-26 2018-07-26
PCT/US2019/030444 WO2019217203A1 (en) 2018-05-11 2019-05-02 Compositions for the treatment of skin conditions

Publications (1)

Publication Number Publication Date
EA202092554A1 true EA202092554A1 (en) 2021-04-12

Family

ID=75817417

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092554A EA202092554A1 (en) 2018-07-26 2019-05-02 COMPOSITIONS FOR TREATMENT OF SKIN DISEASES

Country Status (1)

Country Link
EA (1) EA202092554A1 (en)

Similar Documents

Publication Publication Date Title
MX2020012018A (en) Compositions for the treatment of skin conditions.
MX2017013562A (en) Microbiome regulators and related uses thereof.
WO2017219029A8 (en) Compositions and methods for the depletion of cd117+cells
MX2018001532A (en) Anti-angptl8 antibodies and uses thereof.
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
EA201890725A1 (en) PHARNESIDE X-RECEPTOR AGONISTS AND THEIR APPLICATION
PH12020552229A1 (en) Il-11ra antibodies
MX2023007212A (en) Epinephrine spray formulations.
EA201591427A1 (en) COMPOUNDS AND THEIR APPLICATIONS FOR MODULATION OF HEMOGLOBIN
ECSP12012211A (en) COMPOSITIONS OF ANTI-FACTOR ANTI-FACTOR OF NERVOUS GROWTH (NGF)
EA201591426A1 (en) COMPOUNDS AND THEIR APPLICATIONS FOR MODULATION OF HEMOGLOBIN
MX2020005547A (en) Modulators of complement activity.
EA201992707A1 (en) COMPOUNDS AND THEIR APPLICATIONS FOR HEMOGLOBIN MODULATION
ZA202002779B (en) Dantrolene prodrugs and methods of their use
MX2018008644A (en) 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-deca ne derivatives.
EA202090947A1 (en) COMPOSITIONS AND METHODS FOR CD5 + CELL DEPLETION
MX2018008640A (en) 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives.
MX2023014484A (en) Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection.
MX2020004397A (en) Use of amino acid supplementation for improved muscle protein synthesis.
MX2021005245A (en) Oligosaccharide compositions and methods of use thereof.
EA202191115A1 (en) NEW PYRIDAZINES
EA202091112A1 (en) SOCRYSTALS, PHARMACEUTICAL COMPOSITIONS BASED ON THEIR BASED AND METHODS OF TREATMENT FOR THEIR APPLICATION
EA202090260A1 (en) MEANS AND METHODS FOR HUMAN AAV GENOTHERAPY
WO2014100857A8 (en) Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
EA202092554A1 (en) COMPOSITIONS FOR TREATMENT OF SKIN DISEASES